GlassScriptPhysician profile
David A Gross
NPI 1780098814
$57,306.55
in general payments reported to CMS, 2019-2025
23 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2021: $1,041 · 2022: $6,965 · 2023: $13K · 2024: $16K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $27K · Travel and Lodging: $15K · Food and Beverage: $5,240 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,720 · Education: $3.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $27,240.00 |
| Travel and Lodging | $14,792.66 |
| Food and Beverage | $5,239.52 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,720.00 |
| Education | $3.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $40,537.86 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Pascal |
| Recor Medical INC | $6,465.73 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Abbott Laboratories | $2,814.42 | 2019-2025 | Mitraclip, Ultreon, Optis |
| Spectrawave, INC | $1,600.00 | 2025 | Hypervue Imaging System, Starlight Imaging Catheter |
| Medtronic, INC. | $1,274.77 | 2021-2025 | Corevalve Evolut R |
| Boston Scientific Corporation | $1,263.33 | 2022 | |
| Philips North America LLC | $1,137.95 | 2021-2022 | |
| Cardiovascular Systems INC. | $498.36 | 2021-2023 | Diamondback Coronary |
| Inari Medical, INC. | $424.58 | 2021-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Shockwave Medical, INC | $366.27 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Terumo Medical Corporation | $264.13 | 2021 | |
| Penumbra, INC. | $147.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $103.70 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $101.47 | 2019 | |
| Alnylam Pharmaceuticals INC. | $87.68 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $49.79 | 2022-2024 | Repatha |
| Stryker Corporation | $31.71 | 2025 | Clottriever Bold Catheter |
| Cordis US Corp. | $30.82 | 2022 | |
| Chiesi USA, INC. | $26.38 | 2023 | Cleviprex, Kengreal |
| Heartflow, INC. | $23.25 | 2023 | Ffrct |
| Novo Nordisk INC | $22.71 | 2023 | Ozempic |
| Abiomed | $18.77 | 2023 | Impella |
| Novartis Pharmaceuticals Corporation | $15.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.